hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations

**F Wang**<sup>1,4</sup>, **X Xue**<sup>1,4</sup>, **J Wei**<sup>2</sup>, **Y An**<sup>1</sup>, **J Yao**<sup>1,3</sup>, **H Cai**<sup>1</sup>, **J Wu**<sup>2</sup>, **C Dai**<sup>2</sup>, **Z Qian**<sup>2</sup>, **Z Xu**<sup>2</sup> and **Y Miao**<sup>6,1,2</sup>

1Laboratory of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210009, PR China; 2Center for Pancreatic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210009, PR China; 3Department of General Surgery, The First Affiliated Hospital of Yangzhou University, Yangzhou 225001, PR China

**BACKGROUND:** Expression of ABCG2 is normally absent or low in the pancreas, but high in human pancreatic cancer cells. The mechanism by which ABCG2 is altered in human cancers remains unknown.

**METHODS:** We investigated ABCG2 expression in four pancreatic cancer cell lines, and used three microRNA (miRNA) target prediction programmes, and information from the existing literature to predict and identify hsa-miR-520h as an miRNA that targets ABCG2. The function of this miRNA was investigated by transient transfection of the pancreatic cancer cell line PANC-1 with oligonucleotides that mimic hsa-miR-520h.

**RESULTS:** Results showed that both mRNA and protein levels of ABCG2 were reduced, indicating that it was a target of hsa-miR-520h. Introduction of hsa-miR-520h mimics into PANC-1 cells also resulted in inhibition of cell migration and invasion, and reduction of side population cells. Cell proliferation, cell cycle progression and apoptosis were not affected.

**CONCLUSIONS:** We propose that the effects of hsa-miR-520h may be, at least in part, caused by its regulation of ABCG2. Thus, our findings provide a new insight into the function of miRNA in the regulation of ABCG2 expression in pancreatic cancer. Gene therapy using miRNA mimics may therefore be useful as a pancreatic cancer therapy.

**Keywords:** miRNA; ABCG2; migration; invasion; side population cells

Pancreatic cancer is the fourth leading cause of cancer-related death in Western countries and has the lowest patient survival rate of any solid cancer (Jemal et al., 2009). One of the main reasons for its mortality is that pancreatic cancer cells have a high potential for invasion and metastasis. Although invasion and migration are the overwhelming causes of mortality in patients with solid tumours, our understanding of their molecular determinants is limited (Fidler, 2003; Weigelt et al., 2005; Gupta and Massagué, 2006). Studies on tumour invasion and metastasis have revealed a critical role for microRNAs (miRNAs), which are small, endogenous non-coding RNAs that post-transcriptionally regulate a variety of genes pivotal for invasion or metastasis (Lim et al., 2005; Dalmay and Edwards, 2006; Kim et al., 2008).

Expression of ABCG2, also known as breast cancer resistance protein, is normally absent or low in the pancreas (Doyle et al., 1998; Fetsch et al., 2006). However, recent studies show that ABCG2 is overexpressed in pancreatic cancer cells (Köng et al., 2005; Olempska et al., 2007; Guo et al., 2009), in which it alters the cellular epigenetic programming to promote cell survival. Moreover, ABCG2 expression is high in side-population cells of pancreatic and other tumour cell lines, as well as in primary tumour samples (Hirschmann-Jax et al., 2004; Seigel et al., 2005; Haraguchi et al., 2006; Shi et al., 2008; Sung et al., 2008; Dou et al., 2009; Wang et al., 2009; Yajima et al., 2009), in which it is likely to have a key role in xenobiotic protection, and acts as a marker of side-population cells. However, the mechanism by which ABCG2 becomes over-expressed in human cancers remains unknown, and relatively little is known about the mechanisms that normally regulate ABCG2 expression. Previous studies suggested that it may be regulated by DNA methylation (To et al., 2006; Turner et al., 2006), 5′-untranslated region (UTR) variation (Nakanishi et al., 2006), or histone modification (To et al., 2008a). Cytokines and growth factors (Evseenko et al., 2007; Yin et al., 2008), such as transforming growth factor-β, tumour necrosis factor-α, interleukin 1-β, and insulin-like growth factor 2, are proposed to be involved in ABCG2 regulation. The surface protein levels of ABCG2 do not correlate well with mRNA levels in pancreatic cancer cells (Guo et al., 2009), suggesting that protein-regulatory mechanisms, such as post-transcriptional regulation, post-translational modifications, proteolysis, or sequestration in cell compartments, may affect the protein, without changing the transcript levels. Therefore, additional investigations of ABCG2 expression mechanisms in pancreatic cancer are needed.

miRNAs regulate gene expression post-transcriptionally, by pairing with complementary nucleotide sequences in the 3′-UTR of specific target miRNAs (Pillai, 2005; Zamore and Haley, 2005). They also have an important role in regulating diverse cellular processes, including proliferation, differentiation, cell cycle regulation, and apoptosis (Liao et al., 2008; Wang et al., 2008, 2009, 2009; Bandi et al., 2009; Bhattacharya et al., 2009; Noonan et al., 2009; Ribas et al., 2009; Saito et al., 2009; Song et al., 2009; Ostenfeld et al., 2010; Spizzo et al., 2010). miRNAs can function either as tumour suppressors or as oncogenes, depending on the genes they
target (Si et al., 2007; Welch et al., 2007; Aguda et al., 2008; Grady et al., 2008; Agirre et al., 2009; Furuta et al., 2009; Gandelli et al., 2009; Hoffman et al., 2009; Hurst et al., 2009; Lee et al., 2009; Sachdeva et al., 2009; Tsang and Kwok, 2009; Wu et al., 2009; Aqeilan et al., 2010). Deletion or loss of a suppressive miRNA results in overexpression of target oncogenes, or conversely, activation or overexpression of an oncogenic miRNA results in silencing of tumour-suppressor targets. Thus, oncogenic miRNAs are usually overexpressed in tumours. For example, miR-125a, miR-10a, miR-21, miR-222, miR-125b, miR-7, miR-452, miR-10b, miR-373, and miR-520c induce cell migration and invasion when overexpressed in tumours or tumour cell lines (Ma et al., 2007; Asangani et al., 2008; Huang et al., 2008; Yan et al., 2008; Zhang et al., 2008; Zhu et al., 2008; Cowden Dahl et al., 2009; Qian et al., 2009; Veerla et al., 2009; Weiss et al., 2009). In contrast, suppressive miRNAs such as miR-193b, miR-122, miR-15a, miR-16–1, miR-200, miR-221, miR-126*, miR-335, miR-146a, and miR-29c lead to carcinogenesis, tumour growth, and invasion when downregulated (Le Sage et al., 2007; Bonci et al., 2008; Korpal et al., 2008; Lin et al., 2008; Musiyeiko et al., 2008; Sengupta et al., 2008; Tavazoie et al., 2008; Coulouarn et al., 2009; Li et al., 2009).

In this study, on the basis of previous reports (Liao et al., 2008; To et al., 2008b), we investigated whether hsa-miR-520h targets ABCG2 mRNA. We also investigated the role of hsa-miR-520h in proliferation, cell cycle progression, apoptosis, migration, and invasion in PANC-1 cells. As side-population cells of pancreatic cancer that overexpress ABCG2 have been identified as promoting carcinogenesis, tumour growth, and invasion when downregulated (Le Sage et al., 2007; Bonci et al., 2008; Korpal et al., 2008; Lin et al., 2008; Musiyeiko et al., 2008; Sengupta et al., 2008; Tavazoie et al., 2008; Coulouarn et al., 2009; Li et al., 2009).

TARGET PREDICTION

Three online programs, miRanda (http://www.microrna.org/microrna/home.do), TargetScan (http://www.targetscan.org), and TarBase (http://diana.cslab.ece.ntua.gr/tarbase), were used in combination with previous reports, for predicting miRNAs that might target ABCG2. PANC-1 cells overexpressing ABCG2 were used for target miRNA verification.

miRNA transfection

miRNAs were designed and synthesised by GenePharma (Shanghai, China). hsa-miR-520h mimics were sense: 5'-ACAAGUGUUCUCUUAGAGU-3' and anti-sense: 5'-UCUAAAGGAAGCAACUUUGUUU-3'. Negative controls were sense: 5'-UUUCUCGGAACGUUGACGCGGGTT-3' and anti-sense: 5'-ACGUGACGUGACGUGAGAATT-3'. MicroRNA transfection was performed using Lipofectamine 2000 (Invitrogen). PANC-1 cells were grown in six-well plates to 50% confluence before transfection. Total RNA and protein were extracted at 24 h post-transfection and used for quantitative real-time PCR (qRT–PCR) and western blot analysis. Transfections were the following: hsa-miR-520h mimics (miR-520h), negative control miRNA mimics (NC) and blank control culture medium (Mock).

qRT–PCR AND WESTERN BLOT

Total RNA was extracted from cultured or transfected cells using Trizol (Invitrogen). ABCG2 mRNA was detected by qRT-PCR.
(Takara, Dalian, China) and normalised to β-actin. Polymerase chain reaction primers used were the following: ABCG2 sense: 5'-AATACATCAGCGGATACTACAGG-3', anti-sense: 5'-AGCCACCTCATAAGGGTAAACAT-3'; β-actin sense: 5'-AGAAAATCTGGCACCACACC-3', anti-sense: 5'-TAGACACAGGCYGGATAGCAA-3'. Reactions were performed using an ABI PRISM 7000 Sequence Detection system (Applied Biosystems, Foster City, CA, USA). Cultured or transfected cells were lysed using RIPA buffer with 1% PMSF. Protein concentration was estimated using a BCA kit (Keygen, Nanjing, China). Protein was resolved with 10% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes, which were blocked with 5% non-fat milk in Tris-buffered saline for 3 h and incubated overnight with primary antibodies against ABCG2 (Abcam, Cambridge, MA, USA) or β-actin (Santa Cruz, Santa Cruz, CA, USA). Membranes were incubated for 2 h with horseradish peroxidase-conjugated goat anti-rabbit or goat anti-mouse (Santa Cruz) secondary antibody and visualised with an electrochemiluminescence kit (Pierce, Rockford, IL, USA).

Cell proliferation, cell cycle, and apoptosis analysis

Cell proliferation was determined using an MTT assay. PANC-1 cells were seeded in 96-well culture plates (Costar, Cambridge) at a density of 1 × 10^5 cells per well, transfected with the indicated miRNA and incubated for 24 h before adding 10 μl of MTT reagent to each well and incubating at 37°C for 4 h; thereafter, the medium was replaced with 150 μl dimethyl sulphoxide (DMSO) and oscillated for 10 min. Viable cells were measured by absorbance at 490 nm wavelength using a microplate reader.

Cell cycle and apoptosis were assessed by flow cytometry (Becton Dickinson, San Jose, CA, USA). PANC-1 cells were grown and transfected as above. For cell cycle analysis, cells were collected, washed with phosphate-buffered saline (PBS) and fixed in ethanol at −20°C overnight before being collected by centrifugation, washed with PBS, and resuspended in 500 μl of PBS with 0.2% Triton X-100, 10 mM EDTA, 100 μg ml⁻¹ RNase A, and 50 μg ml⁻¹ propidium iodide (PI) at room temperature for 30 min. For cell apoptosis, cells were collected, washed with PBS, suspended in 100 μl 1 × binding buffer, stained with 5 μl annexin-fluorescein isothiocyanate (FITC), and 5 μl PI at room temperature for 15 min in the dark.

Cell migration and invasion analysis

Cell migration and invasion were assayed using a chamber of 6.5 mm in diameter, with 8 μm pore size (Corning, Corning, NY, USA). At 24 h post-transfection, PANC-1 cells were added to the upper chamber, which was coated with 1 mg ml⁻¹ matrigel for invasion assays, and 0.6 ml of 10% FBS-DMEM was added to the lower chamber. Cells were incubated for 24 h at 37°C, and non-migrating or non-invading cells were removed with cotton swabs.

Figure 3 Effect of hsa-miR-520h on cell proliferation, cell cycle, and apoptosis of PANC-1 cells. (A) The proliferation ability of PANC-1 cells at 24 h post-transfection with hsa-miR-520h mimic was detected by MTT assay. The data are mean ± s.d. from three independent experiments (*P<0.05, compared with control). (B) Cell cycle analysis of PANC-1 cells at 24 h post-transfection was analysed by flow cytometry. 2N: cells have diploid DNA content; 4N: cells have tetraploid DNA content. (C) Apoptosis of PANC-1 cells at 24 h post-transfection was monitored by flow cytometry. LR is indicative of apoptosis.
Cells migrating to or invading the bottom of the membrane were stained with 0.1% crystal violet for 30 min at 37°C, and washed with PBS. Stained cells were soaked in 33% ice-cold acetic acid and oscillated for 10 min. Cell migration or invasion was assessed by absorbance at 570 nm wavelength using a microplate reader (Tecan, Shanghai, China).

Side-population cell analysis

For analysis of side-population cells, PANC-1 cells were transfected with miRNA for 24 h, then incubated with Hoechst 33342 (5 μmol ml⁻¹, Sigma) for 90 min at 37°C, either alone or in combination with 50 μmol per ml verapamil. Cells were analysed in a FACS Vantage cell sorter (Becton Dickinson) using dual-wavelength analysis (blue 425 nm, red 675 nm) after excitation with 350 nm UV light. Propidium iodide-positive cells were excluded.

Statistical analysis

Each experiment was conducted at least three times. All values were reported as mean ± s.d. Differences between experimental groups and controls were assessed by Student’s t-test using Excel software. P < 0.05 was considered statistically significant.

RESULTS

Pancreatic cancer cell lines expressed variable levels of ABCG2

Recent studies have revealed that ABCG2 is overexpressed in many human cancers. Therefore, we checked the expression of ABCG2 in four human malignant pancreatic cancer cell lines: BxPC-3, CFPAC-1, PANC-1, and SW1990. BxPC-3 and CFPAC-1 are low-grade cancer cell lines, and PANC-1 and SW1990 are high-grade lines. Western blot analysis showed that ABCG2 was overexpressed in PANC-1 and SW1990 cells, and underexpressed in BxPC-3 and CFPAC-1 cells (Figure 1A). These results were confirmed by qRT-PCR analysis (Figure 1B).

hsa-miR-520h targets ABCG2

Using miRNA target predicting programmes and previous reports, we hypothesised that the miRNA hsa-miR-520h targeted ABCG2, and we chose PANC-1 cells to test our hypothesis. To verify our predicted target of hsa-miR-520h, we transfected PANC-1 cells with hsa-miR-520h mimics (miR-520h), negative control miRNA mimics (NC), and blank control culture medium (mock). Western blot analysis showed that, at 24 h post-transfection, overexpression of hsa-miR-520h resulted in a significant decrease of endogenous ABCG2 protein levels, compared with cells transformed with NC or
mock (Figure 2A). Inhibition of expression by miRNAs mediates mRNA levels; hence we used qRT–PCR to examine ABCG2's mRNA levels. Overexpression of hsa-miR-520h in PANC-1 cells led to a corresponding decrease of endogenous ABCG2 mRNA at 24 h post-transfection (Figure 2B). These observations suggested that hsa-miR-520h downregulates ABCG2 expression by inhibiting translation or causing mRNA instability. Taken together, these data indicate that hsa-miR-520h targets ABCG2.

**Effects of hsa-miR-520h on proliferation, cell cycle, and apoptosis**

To investigate whether hsa-miR-520h influenced cell proliferation, cell cycle, or apoptosis of PANC-1 cells by inhibiting translation of the indicated target ABCG2 mRNA, we transiently transfected PANC-1 cells with hsa-miR-520h mimics for 24h. Ectopic expression of hsa-miR-520h had no significant inhibition on cell proliferation compared with that of control groups (Figure 3A). The cell cycle distribution of transfected cells was examined by flow cytometry, with no significant G0/G1 accumulation phenotype in PANC-1 cells transfected with hsa-miR-520h (56.43%) compared with NC (55.34%) or mock (49.68%) control-transfected cells (Figure 3B). We also examined the cell apoptosis of transfected cells by flow cytometry, and found no significant increase in apoptosis in PANC-1 cells transfected with hsa-miR-520h (7.31%) compared with NC (6.45%) or mock (5.70%) transfected cells (Figure 3C).

**hsa-miR-520h inhibits migration and invasion of PANC-1 cells**

To determine whether hsa-miR-520h and its target gene are associated with tumour migration and invasion, we transfected PANC-1 cells with hsa-miR-520h mimics or NC, or subjected them to mock transfection, and evaluated cell migration and invasion. As shown in Figure 4A and B, the migration ability of hsa-miR-520h mimic-transfected cells was significantly decreased by 55%, compared with that of controls. A matrigel invasion assay was performed in parallel to determine the effect of transfection with hsa-miR-520h mimics. As shown in Figure 4A and C, the invasion ability of hsa-miR-520h-transfected cells was significantly decreased by 53%, compared with that of controls. Taken together, these results suggested that hsa-miR-520h functions as a potent suppressor of PANC-1 cell migration and invasion through downregulation of ABCG2 expression.

**hsa-miR-520h depletes the side population of PANC-1 cells**

Previous studies suggested that ABCG2 has an important role in the identity of side-population cells. Therefore, we examined the influence of hsa-miR-520h on the population of tumour cells that exclude Hoechst 33342 dye, a strategy that is used to identify side-population cells. Flow cytometry of hsa-miR-520h-transfected PANC-1 cells showed that the side population was 1.51%, compared with 2.79% in NC-transfected and 3.06% in mock-transfected cells (Figure 5). These data indicated that

---

**Figure 5** Overexpression of hsa-miR-520h decreases the side-population compartment of PANC-1 cells. Side-population cells of PANC-1 cells transfected with hsa-miR-520h account for 1.51% of the total number of cells, compared with 2.79% for NC-treated, or 3.06% for mock-treated, as measured by FACS analysis.
hsa-miR-520h has a critical role in the identification of the side population, through downregulation of ABCG2 expression.

DISCUSSION

To investigate the interaction between miRNAs and their target genes in pancreatic cancer, we determined the expression levels of ABCG2 in four pancreatic cancer cell lines. Both western blot and qRT–PCR analysis showed that the cell lines expressed variable levels of ABCG2, with high expression in PANC-1 and SW1990 cells, and low expression in BxPC-3 and CPFPAC-1 cells (Figure 1). We used miRNA target prediction programmes and previous studies to find an miRNA that potentially regulated ABCG2, and selected PANC-1 cells for verification using transfected miRNA mimics. In the transfected cells, ABCG2 was downregulated at both the miRNA and protein levels by the proposed target miRNA, hsa-miR-520h (Figure 2). These data suggested that ABCG2 is a target of hsa-miR-520h in pancreatic cells.

Overexpression of ABCG2 promotes migration and invasion in a variety of different tumour types (Mohan et al, 2006; Ho et al, 2007; Chiou et al, 2008; Okamoto et al, 2009). The mechanism by which ABCG2 becomes overexpressed is not entirely clear, but a possible mechanism is through miRNA regulation. MicroRNAs can function as tumour suppressors, oncogenes, or as promoters or suppressors of metastasis. We transfected hsa-miR-520h into PANC-1 cells and observed cell proliferation, cycle, apoptosis, migration, and invasion. Introduction of hsa-miR-520h resulted in a significant decrease in cell migration and invasion, but with no significant effects on cell proliferation, cell cycle distribution, or apoptosis (Figures 3 and 4). This is the first study to show that hsa-miR-520h inhibits migration and invasion in pancreatic cancer cells, through a possible mechanism of negative regulation of ABCG2 expression.

In this study, FACS analysis at 24 h after transfection of PANC-1 cells with miRNA mimics showed a remarkable decrease in the proportion of side-population cells (Figure 5). Therefore, we propose that hsa-miR-520h may have a critical role in carcinogenesis by way of affecting side-population cells by influencing ABCG2 expression. However, Patrawala et al (2005) reported that ABCG2-positive and -negative tumour cells have similar tumourigenicity; hence, the precise reasons why ABCG2 is associated with pancreatic cancer cells require further study.

In conclusion, we show that hsa-miR-520h has a key role not only in inhibiting migration and invasion, but also in decreasing the proportion of side-population cells of PANC-1. The possible mechanism of these effects may be through downregulation of ABCG2 expression. As no effective approaches for curing pancreatic cancer exist at present, we propose that gene therapy targeting hsa-miR-520h/ABCG2 should be investigated further as a potential alternative therapeutic strategy for pancreatic cancer.

ACKNOWLEDGEMENTS

This study was supported by a Natural Science Foundation of China grant (30972912).

REFERENCES

Agirre X, Vilas-Zornoza A, Jiménez-Velasco A, Martín-Subero JI, Cordeu L, Gárate L, San José-Eneriz E, Abizanda G, Rodríguez-Otero P, Fortes P, Ríofín J, Bandrés E, Calasanz MJ, Martín V, Heiniger A, Torres A, Siebert R, Román-Gomez J, Prósper F (2009) Epigenetic silencing of the tumour suppressor microRNA hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 69: 4443–4453
Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB (2008) MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17–92, EZF, and Myc. Proc Natl Acad Sci USA 105: 19678–19683
Aqelian RI, Calin GA, Croce CM (2010) miR-15a and miR-16–1 in cancer: discovery, function and future perspectives. Cell Death Differ 17: 215–220
Asangani IA, Rasheed SA, Nikolova DA, Leopold JH, Colburn NH, Post S, Allgayer H (2008) MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdc4d and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27: 2128–2136
Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, Kappeler A, Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, Kappeler A, Brunner T, Vassela E (2009) miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 69: 9090–9095
Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D’Urso L, Pagliuca A, Biffoni M, Labbaye C, Butticci M, Muto G, Peschle C, De Maria R (2008) The miR-15a-miR-16–1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271–1277
Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, Chou SH, Chien CS, Ku HH, Lo JP (2008) Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 14: 4085–4095
Cowden Dahl KD, Dahl R, Kruchak JN, Hudson LG (2009) The epidermal growth factor receptor responsive miR-125a represses mesenchymal epithelial morphology in ovarian cancer cells. Neoplasia 11: 1208–1215
Dalmay T, Edwards DR (2006) MicroRNAs and the hallmarks of cancer. Oncogene 25: 6170–6175
Dou J, Wen P, Hu H, Li Y, Wu Y, Liu C, Zhao F, Hu K, Wang J, Jiang C, He X, Gu N (2009) Identifying tumor stem-like cells in mouse melanoma cell lines by analyzing the characteristics of side population cells. Cell Biol Int 33: 807–815
Doyle LA, Yang W, Abuzzo LE, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95: 15665–15670
Eveenko DA, Paxton JW, Keelan JA (2007) Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab Dispos 35: 595–601
Fetsch PA, Abati A, Litman T, Morisaki K, Honjo Y, Mittal K, Bates SE (2006) Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett 235: 84–92
Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3: 453–458
Furuta M, Kozaki KI, Tanaka S, Arita S, Imoto I, Inazawa J (2009) miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 31(3): 766–774
Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, Valdagni R, Daidone MG, Zaffaroni N (2009) miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsisilon. Cancer Res 69: 2287–2295
Grady WM, Parkin RK, Mitchell PS, Lee JH, Kim YH, Tsuchiya KD, Washington MK, Paraskeva C, Willson JK, Kaz AM, Kroh EM, Allen A, Fritz BR, Markowitz SD, Tewari M (2008) Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 27: 3880–3888
Guo J, Anderson MG, Tapang P, Palma JP, Rodriguez LE, Niquette A, Li J, Bouska JI, Wang G, Semizarov D, Albert DH, Donawho CK, Glaser KB, Shah OJ (2009) Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152. Pharmacogenomics J 9: 90–102
Okamoto A, Chikamatsu K, Sakakura K, Hattusihka K, Takahashi G, Masuyama K (2009) Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck. Oral Oncol 45: 633 – 639

Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H (2007) Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 6: 92 – 97

Ostenfels MF, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sorensen KD, Ulhøi B, Borre M, Kjems J, Dyrskjøt L, Orntoft TF (2010) miR-145 induces caspase-dependent and -independent cell death in uterine cervical cancer cells with targeting of an expression signature present in Ta bladder tumors. Oncogene 29: 1073 – 1084

Patrawala L, Calhoun T, Brobbourard R, Zhou J, Claypool K, Tang D (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 65: 6207 – 6219

Pillai RS (2005) MicroRNA function: multiple mechanisms for a tiny RNA? RNA 11: 1753 – 1761

Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H (2009) High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta. Breast Cancer Res Treat 117: 131 – 140

Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegenusubramanian S, Luo J, Rodriguez R, Mandell JT, Lupold SE (2009) miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 69: 7165 – 7169

Sachdeva M, Zhu S, Wu F, Wu H, Vaila V, Kumar S, Elble R, Watabe K, Mo YY (2009) p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 106: 3207 – 3212

Saito Y, Suzuki H, Tsugawa H, Nakagawa I, Matsuizki J, Kanai Y, Hit H (2007) Chromatin remodelling at Alu repeats by epigenetic treatment activates silenced microRNA-512–5p with downregulation of Mc1-r in human gastric cancer cells. Oncogene 28: 2738 – 2744

Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F (2005) Cancer stem cell characteristics in retinoblastoma. Mol Vis 11: 729 – 737

Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ, Chu YC, Hildesheim A, Sugden B, Ahluquist P (2008) MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 105: 5874 – 5878

Shi GM, Xu Y, Fan J, Zhou J, Yang XR, Qiu SJ, Liao Y, Wu WZ, Ji Y, Ke AW, Ding ZB, He YZ, Wu B, Yang GH, Qin WZ, Zhang W, Zhu J, Min ZH, Wu ZQ (2008) Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol 134: 1155 – 1163

Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY (2007) miR-21-mediated tumor growth. Oncogene 26: 2799 – 2803

Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Bottchinka GI, Gavin E, Wan Y, Fabbri M, Posturi F, Cattani A, O’Connor DM, Do J (2009) Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28: 4065 – 4074

Spizzo R, Nicolo M, Lupini L, Lu Y, Fogyart J, Rossi S, Zagatti B, Fabbrini M, Veronese A, Liu X, Davuluri R, Croce CM, Mills G, Negrini M, Calin GA (2010) miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha mRNA in human breast cancer cells. Cell Death Differ 17: 246 – 254

Sung JM, Cho HJ, Yi H, Lee CH, Kim HS, Kim DK, Abd El-Aty AM, Kim JS, Sung B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Fabbri M, Posturi F, Cattani A, O’Connor DM, Do J (2009) Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28: 4065 – 4074

To KK, Polgar O, Huff LM, Morisaki K, Bates SE (2008a) Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Cell Death Differ 17: 263 – 274

Tavares SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451: 147 – 152

To KK, Polgar O, Huff LM, Morisaki K, Bates SE (2008b) Regulation of ABCG2 expression at the 3‘ untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol 28: 5147 – 5161
Tsang WP, Kwok TT (2009) The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 30: 953–959
Turner JG, Gump JL, Zhang G, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM (2006) ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood 108: 3881 – 3889
Veena S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, Liedberg F, Chebil G, Gudjonsson S, Borg A, Månsson W, Rovira C, Höglund M (2009) MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 124: 2236 – 2242
Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko Jr RJ, Lazo JS, Wang Z, Zhang L, Yu J (2009) microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 69: 8157 – 8165
Wang Q, Li YC, Wang J, Kong J, Qi Y, Quigg RJ, Li X (2008) miR-17–92 cluster accelerates adipocyte differentiation by negatively regulating tumor-suppressor Rb2/p130. Proc Natl Acad Sci USA 105: 2889 – 2894
Wang X, Wang HK, McCoy JP, Banerjee NS, Rader JS, Broker TR, Meyers C, Chow LT, Zheng ZM (2009) Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 15: 637 – 647
Wang YH, Li F, Luo B, Wang XH, Sun HC, Liu S, Cui YQ, Xu XX (2009) A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasma 56: 371 – 378
Weigelt B, Peterse JL, van ’t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5: 591 – 602
Weiss FU, Marques JI, Woltering JM, Vlecken DH, Aghdassi A, Partecke LI, Heidecke CD, Lerch MM, Bagowski CP (2009) Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer. Gastroenterology 137: 2136 – 2145
Welch C, Chen Y, Stallings RL (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26: 5017 – 5022
Wu H, Zhu S, Mo YY (2009) Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 19: 439 – 448
Yajima T, Ochiai H, Uchiyama T, Takano N, Shibahara T, Azuma T (2009) Resistance to cytotoxic chemotherapy-induced apoptosis in side population cells of human oral squamous cell carcinoma cell line Ho-1-N-1. Int J Oncol 35: 273 – 280
Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YY, Shao JY (2008) MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14: 2348 – 2360
Yin L, Castagnino P, Asooai RK (2008) ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition. Cancer Res 68: 800 – 807
Zamore PD, Haley B (2005) Ribonome: the big world of small RNAs. Science 309: 1519 – 1524
Zhang Z, Li Z, Gao C, Chen P, Chen J, Liu W, Xiao S, Lu H (2008) miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest 88: 1358 – 1366
Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY (2008) MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18: 350 – 359

hsa-miR-520h downregulates ABCG2
F Wang et al

British Journal of Cancer (2010) 103(4), 567 – 574 © 2010 Cancer Research UK